Shukla Swati, Srivastava Arpna, Kumar Sunil, Singh Usha, Goswami Sandeep, Chawla Bhavna, Bajaj Mandeep Singh, Kashyap Seema, Kaur Jasbir
Department of Ocular Biochemistry, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India.
Oculoplasty & Pediatric Opthalmology Services, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India.
Int J Ophthalmol. 2017 Nov 18;10(11):1655-1661. doi: 10.18240/ijo.2017.11.04. eCollection 2017.
To elucidate the mechanism of multidrug resistance in retinoblastoma, and to acquire more insights into drug resistance.
Three anticancer drug resistant Y79 human RB cells were generated against vincristine, etoposide or carboplatin, which are used for conventional chemotherapy in RB. Primary cultures from enucleated eyes after chemotherapy (PCNC) were also prepared. Their chemosensitivity to chemotherapeutic agents (vincristine, etoposide and carboplatin) were measured using MTT assay. Western blot analysis was performed to evaluate the expression of p53, Bcl-2 and various multidrug resistant proteins in retinoblastoma cells.
Following exposure to chemotherapeutic drugs, PCNC showed less sensitivity to drugs. No significant changes observed in the p53 expression, whereas Bcl-2 expression was found to be increased in the drug resistant cells as well as in PCNC. Increased expression of P-glycoprotein (P-gp) was observed in drug resistant Y79 cells; however there was no significant change in the expression of P-gp found between primary cultures of primarily enucleated eyes and PCNC. Multidrug resistance protein 1 (Mrp-1) expression was found to be elevated in the drug resistant Y79 cells as well as in PCNC. No significant change in the expression of lung resistance associated protein (Lrp) was observed in the drug resistant Y79 cells as well as in PCNC.
Our results suggest that multidrug resistant proteins are intrinsically present in retinoblastoma which causes treatment failure in managing retinoblastoma with chemotherapy.
阐明视网膜母细胞瘤多药耐药的机制,以更深入了解耐药性。
针对长春新碱、依托泊苷或卡铂(用于视网膜母细胞瘤的常规化疗),构建了三种抗癌药耐药的Y79人视网膜母细胞瘤细胞。还制备了化疗后摘除眼球的原代培养物(PCNC)。使用MTT法测定它们对化疗药物(长春新碱、依托泊苷和卡铂)的化学敏感性。进行蛋白质免疫印迹分析以评估视网膜母细胞瘤细胞中p53、Bcl-2和各种多药耐药蛋白的表达。
暴露于化疗药物后,PCNC对药物的敏感性较低。p53表达未观察到显著变化,而耐药细胞以及PCNC中Bcl-2表达增加。在耐药的Y79细胞中观察到P-糖蛋白(P-gp)表达增加;然而,在初次摘除眼球的原代培养物和PCNC之间,P-gp表达没有显著变化。多药耐药蛋白1(Mrp-1)在耐药的Y79细胞以及PCNC中表达升高。在耐药的Y79细胞以及PCNC中,未观察到肺耐药相关蛋白(Lrp)表达的显著变化。
我们的结果表明,多药耐药蛋白在视网膜母细胞瘤中固有存在,这导致视网膜母细胞瘤化疗治疗失败。